Patients posing a serious suicidal risk and/or violence as judged by the investigator;
Delirium
Dementia
Amnestic and other cognitive disorder;
Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months;
Patients who meet DSM-IV-TR criteria for any significant current substance abuse;
hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;
malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;
significant unstable medical condition or life threatening disease with anticipated survival of less than 6 months;
need for therapies that may obscure the results of treatment and/or of the study
Participation in another clinical trial within 30 days of the screening visit;
Anticipated inability to attend scheduled study visits;
Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;
Patients with a history of prior pharmacogenomic testing;
Any change in psychotropic medication (including change in dosage) between screening and baseline;
Patients who are known to be pregnant or lactating;
Patients with a history of gastric bypass surgery.

NCT02573168_exc_T1
Observation
suicidal risk
NCT02573168_exc_T2
Observation
violence
NCT02573168_exc_T3
Condition
Delirium
NCT02573168_exc_T4
Condition
Dementia
NCT02573168_exc_T5
Condition
cognitive disorder
NCT02573168_exc_T6
Condition
estic an order;
P
NCT02573168_exc_T7
Condition
hypothyroidism
NCT02573168_exc_T8
Negation
unless
NCT02573168_exc_T9
Drug
thyroid medication
NCT02573168_exc_T10
Condition
substance abuse
NCT02573168_exc_T11
Measurement
DSM-IV-TR
NCT02573168_exc_T12
Condition
hepatic insufficiency
NCT02573168_exc_T13
Measurement
aspartate aminotransferase
NCT02573168_exc_T14
Measurement
AST
NCT02573168_exc_T15
Measurement
alanine aminotransferase
NCT02573168_exc_T16
Measurement
ALT
NCT02573168_exc_T17
Value
three times the upper limit of normal
NCT02573168_exc_T18
Scope
aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)
NCT02573168_exc_T19
Procedure
liver transplant
NCT02573168_exc_T20
Condition
cirrhosis of the liver
NCT02573168_exc_T21
Condition
malignancy
NCT02573168_exc_T22
Negation
except
NCT02573168_exc_T23
Condition
basal cell carcinoma
NCT02573168_exc_T24
Procedure
chemotherapy
NCT02573168_exc_T25
Temporal
within 1 year prior to screening
NCT02573168_exc_T26
Reference_point
screening
NCT02573168_exc_T27
Condition
malignancy
NCT02573168_exc_T28
Temporal
more than 1 year
NCT02573168_exc_T29
Qualifier
local
NCT02573168_exc_T30
Negation
without
NCT02573168_exc_T31
Condition
metastasis
NCT02573168_exc_T32
Condition
recurrence
NCT02573168_exc_T33
Scope
metastasis and/or recurrence
NCT02573168_exc_T34
Condition
medical condition
NCT02573168_exc_T35
Qualifier
unstable
NCT02573168_exc_T36
Condition
life threatening disease
NCT02573168_exc_T37
Observation
anticipated survival
NCT02573168_exc_T38
Value
less than 6 months
NCT02573168_exc_T39
Scope
unstable medical condition or life threatening disease
NCT02573168_exc_T45
Procedure
psychotropic medication
NCT02573168_exc_T47
Procedure
gastric bypass surgery